Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

<p>Abstract</p> <p>Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most...

Full description

Bibliographic Details
Main Authors: Bacchiocchi Antonella, Cheng Elaine, Ariyan Stephan, Pavlick Anna C, Sznol Mario, Rubinstein Jill C, Kluger Harriet M, Narayan Deepak, Halaban Ruth
Format: Article
Language:English
Published: BMC 2010-07-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/8/1/67
Description
Summary:<p>Abstract</p> <p>Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most common mutation, yet patients with this variant are currently excluded from the PLX4032 trials. Here we present evidence that a patient bearing the BRAF V600K mutation responded remarkably to PLX4032, suggesting that clinical trials should include all patients with activating BRAF V600E/K mutations.</p>
ISSN:1479-5876

Similar Items